| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shuangmin Ji, Dewei Shang, Kehua Wu, Anning Li, Xiwei Li, Chenhui Deng, Liang Li, Tianyan Zhou, Chuanyue Wang, Wei L. Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients. International journal of clinical pharmacology and therapeutics. vol 54. issue 5. 2016-06-29. PMID:27007997. |
population pharmacokinetic-pharmacodynamic (poppk/pd) modeling of risperidone and its active metabolite in chinese schizophrenia patients. |
2016-06-29 |
2023-08-13 |
Not clear |
| Shuangmin Ji, Dewei Shang, Kehua Wu, Anning Li, Xiwei Li, Chenhui Deng, Liang Li, Tianyan Zhou, Chuanyue Wang, Wei L. Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients. International journal of clinical pharmacology and therapeutics. vol 54. issue 5. 2016-06-29. PMID:27007997. |
risperidone is a second-generation antipsychotic agent commonly used in the treatment of ~ 31.1% of schizophrenia patients in china, it is the most commonly-prescribed antipsychotic agent. |
2016-06-29 |
2023-08-13 |
Not clear |
| Shuangmin Ji, Dewei Shang, Kehua Wu, Anning Li, Xiwei Li, Chenhui Deng, Liang Li, Tianyan Zhou, Chuanyue Wang, Wei L. Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients. International journal of clinical pharmacology and therapeutics. vol 54. issue 5. 2016-06-29. PMID:27007997. |
despite the abundant use of risperidone, population pharmacokinetic-pharmacodynamic models of risperidone have not been performed in chinese schizophrenia patients. |
2016-06-29 |
2023-08-13 |
Not clear |
| Sushil Thomas Alexander, Dheeraj Kattula, Pavithra Mannam, Ramya Iyyadura. Risperidone Induced Benign Intracranial Hypertension Leading to Visual Loss. Indian journal of psychological medicine. vol 38. issue 3. 2016-06-23. PMID:27335522. |
we report the case of a 40-year-old obese lady being treated with risperidone for schizophrenia who presented with features of bih. |
2016-06-23 |
2023-08-13 |
Not clear |
| Ju-Yeon Lee, Sung-Wan Kim, Yo-Han Lee, Hee-Ju Kang, Seon-Young Kim, Kyung-Yeol Bae, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoo. Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy. Human psychopharmacology. vol 30. issue 6. 2016-06-17. PMID:26123060. |
factors associated with self-rated sexual function in korean patients with schizophrenia receiving risperidone monotherapy. |
2016-06-17 |
2023-08-13 |
Not clear |
| Leonel E Rojo, Pablo A Gaspar, H Silva, L Risco, Pamela Arena, Karen Cubillos-Robles, Belen Jar. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacological research. vol 101. 2016-06-10. PMID:26218604. |
second generation antipsychotics (sgas), such as clozapine, olanzapine, risperidone and quetiapine, are among the most effective therapies to stabilize symptoms schizophrenia (sz) spectrum disorders. |
2016-06-10 |
2023-08-13 |
Not clear |
| M Kolek, J Duba, S Vesela, B Pasztor, J Doleckov. Cost-Utility Analysis of Long-Acting Paliperidone in Comparison with Oral Risperidone, Oral Paliperidone and Long-Acting Risperidone in the Maintenance Treatment of Schizophrenia in the Czech Republic. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 17. issue 7. 2016-06-10. PMID:27201283. |
cost-utility analysis of long-acting paliperidone in comparison with oral risperidone, oral paliperidone and long-acting risperidone in the maintenance treatment of schizophrenia in the czech republic. |
2016-06-10 |
2023-08-13 |
Not clear |
| Sheng-Yu Lee, Shiou-Lan Chen, Yun-Hsuan Chang, Po-See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Liang-Jen Wang, I-Hui Lee, Tzu-Yun Wang, Kao-Chin Chen, Yen-Kuang Yang, Jau-Shyong Hong, Ru-Band L. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan. Journal of psychiatric research. vol 69. 2016-06-07. PMID:26343594. |
whether treating schizophrenia with risperidone plus add-on dm is more effective than risperidone (risp) alone, and the association between the aldh2 polymorphism and treatment response were investigated. |
2016-06-07 |
2023-08-13 |
Not clear |
| Huafang Li, Chen Yao, Jianguo Shi, Fude Yang, Shuguang Qi, Lili Wang, Honggeng Zhang, Jie Li, Chuanyue Wang, Chuansheng Wang, Cui Liu, Lehua Li, Qiang Wang, Keqing Li, Xiaoyan Luo, Niufan G. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. Journal of psychiatric research. vol 69. 2016-06-07. PMID:26343601. |
comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in chinese patients: a double-blind, parallel-group multicenter randomized trial. |
2016-06-07 |
2023-08-13 |
Not clear |
| Huafang Li, Chen Yao, Jianguo Shi, Fude Yang, Shuguang Qi, Lili Wang, Honggeng Zhang, Jie Li, Chuanyue Wang, Chuansheng Wang, Cui Liu, Lehua Li, Qiang Wang, Keqing Li, Xiaoyan Luo, Niufan G. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. Journal of psychiatric research. vol 69. 2016-06-07. PMID:26343601. |
this randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat chinese schizophrenia patients aged ≥18 and < 65 years. |
2016-06-07 |
2023-08-13 |
Not clear |
| Huafang Li, Chen Yao, Jianguo Shi, Fude Yang, Shuguang Qi, Lili Wang, Honggeng Zhang, Jie Li, Chuanyue Wang, Chuansheng Wang, Cui Liu, Lehua Li, Qiang Wang, Keqing Li, Xiaoyan Luo, Niufan G. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. Journal of psychiatric research. vol 69. 2016-06-07. PMID:26343601. |
in conclusion, blonanserin was as effective as risperidone for the treatment of chinese patients with schizophrenia. |
2016-06-07 |
2023-08-13 |
Not clear |
| Arija Maat, Wiepke Cahn, Harm J Gijsman, Johannes E Hovens, René S Kahn, André Alema. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 4. 2016-05-06. PMID:24418213. |
open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. |
2016-05-06 |
2023-08-12 |
Not clear |
| Arija Maat, Wiepke Cahn, Harm J Gijsman, Johannes E Hovens, René S Kahn, André Alema. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 4. 2016-05-06. PMID:24418213. |
the goal of this 8-week, randomized, multicenter, open-label study was to examine the effects of aripiprazole and risperidone on social cognition and neurocognition in individuals with schizophrenia. |
2016-05-06 |
2023-08-12 |
Not clear |
| A Schreiner, P Bergmans, P Cherubin, S Keim, P-M Llorca, B Cosar, A Petralia, G Corrivetti, L Hargarte. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. Journal of psychopharmacology (Oxford, England). vol 29. issue 8. 2016-05-06. PMID:25999398. |
paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. |
2016-05-06 |
2023-08-13 |
Not clear |
| A Schreiner, P Bergmans, P Cherubin, S Keim, P-M Llorca, B Cosar, A Petralia, G Corrivetti, L Hargarte. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. Journal of psychopharmacology (Oxford, England). vol 29. issue 8. 2016-05-06. PMID:25999398. |
palmflexs, a prospective multicentre, open-label, 6-month, phase iiib interventional study, explored tolerability, safety and treatment response in adults (n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (pp) after unsuccessful treatment with risperidone long-acting injectable therapy (rlat) or conventional depot antipsychotics (aps). |
2016-05-06 |
2023-08-13 |
Not clear |
| Juliane Heide, Fengyu Zhang, Kristin L Bigos, Stefan A Mann, Vaughan J Carr, Cynthia Shannon Weickert, Melissa J Green, Daniel R Weinberger, Jamie I Vandenber. Differential Response to Risperidone in Schizophrenia Patients by KCNH2 Genotype and Drug Metabolizer Status. The American journal of psychiatry. vol 173. issue 1. 2016-05-06. PMID:26481172. |
differential response to risperidone in schizophrenia patients by kcnh2 genotype and drug metabolizer status. |
2016-05-06 |
2023-08-13 |
Not clear |
| Hsue-Wei Chan, Chin-Yu Huang, Wen-Jui Feng, Yung-Chieh Ye. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. Psychiatry and clinical neurosciences. vol 69. issue 8. 2016-04-25. PMID:25781185. |
risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: a retrospective cohort study. |
2016-04-25 |
2023-08-13 |
Not clear |
| Hsue-Wei Chan, Chin-Yu Huang, Wen-Jui Feng, Yung-Chieh Ye. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. Psychiatry and clinical neurosciences. vol 69. issue 8. 2016-04-25. PMID:25781185. |
we wanted to present a picture of patients with schizophrenia receiving risperidone long-acting injection (rlai) treatment in a real-world setting. |
2016-04-25 |
2023-08-13 |
Not clear |
| Rocco A Zoccali, Antonio Bruno, Maria Rosaria Anna Muscatell. Efficacy and safety of sertindole in schizophrenia: a clinical review. Journal of clinical psychopharmacology. vol 35. issue 3. 2016-04-19. PMID:25830594. |
given current available findings, sertindole is at least effective as haloperidol, risperidone, and olanzapine on schizophrenia symptoms. |
2016-04-19 |
2023-08-13 |
Not clear |
| Richard A Kanaa. Concerns over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia. Schizophrenia research. vol 169. issue 1-3. 2016-04-19. PMID:26560037. |
concerns over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia. |
2016-04-19 |
2023-08-13 |
Not clear |